News

MS Australia statement regarding proposed NDIS changes

30 April 2026

To everyone in the MS community.

For people with MS on the NDIS, disability supports are not discretionary. They are essential. Particularly given the lifelong, progressive and often unpredictable nature of MS.

Recent announcements have outlined a series of reforms aimed at slowing NDIS growth, including the introduction of new planning and assessment frameworks, and measures that will significantly reshape how supports are funded, delivered and managed.

We welcome a number of these changes focused on quality care, including registration requirements for direct care services; and we support a scheme that is sustainable for those with higher support needs, as the scheme was designed. We understand the Government’s need to manage the affordability of the scheme.

There are, however, some changes that, without further detail, may be of concern, including reductions in funding for social and community participation, fewer support coordinators and plan managers; as well as new standardised functional assessments, which may have real implications for people living with MS and other neurological conditions who rely on the scheme.

MS Australia remains steadfast in our commitment to advocate for a better NDIS.

One that is fair, sustainable, and that continues to deliver certainty, dignity and access to vital supports for people living with MS.

As the Government moves forward with legislation, consultation and implementation, we will continue to engage directly with decision‑makers to ensure the lived realities of people with MS are understood and reflected; including the need for ongoing access to appropriate supports and services.

We will continue to stand alongside the MS community, amplify your voices, and push for an NDIS that works for people living with MS and other neurological conditions, now and into the future.

“A sustainable NDIS must also be a fair and accessible NDIS. For people living with MS and other neurological conditions, supports are not discretionary. They are essential. MS Australia will continue to work closely with Government to ensure reform does not come at the expense of people with lifelong neurological conditions.”

Rohan Greenland

CEO, ms australia

Related News

MS News

Thank you! Ocrevus and Kesimpta will remain on the PBS

17 July 2026

The Australian Government has confirmed that Ocrevus and Kesimpta will remain available through the Pharmaceutical Benefits Scheme (PBS), meaning thousands of Australians living with MS can continue to access these life-changing treatments. 

MS News

MS Australia applauds Health Minister’s announcement that Ocrevus and Kesimpta will remain on the PBS

16 July 2026

MS Australia warmly welcomes the announcement from the Minister for Health and Aged Care, the Hon Mark Butler MP, that Ocrevus (ocrelizumab) and Kesimpta (ofatumumab) will remain available through the Pharmaceutical Benefits Scheme (PBS).

MS News

PBS access to two vital MS treatments under threat as Government decision looms

1 July 2026

Multiple disease-modifying therapies (DMTs), Ocrevus (ocrelizumab) and Kesimpta (ofatumumab), are at risk of being withdrawn from the Pharmaceutical Benefits Scheme (PBS), as a consequence of government-driven policy-related price reductions.

Read More

Newsletter subscription

  • This field is for validation purposes and should be left unchanged.

MS Australia statement regarding proposed NDIS changes